+1.54%
Today
Loading 1D prices…
Company profile
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Watertown, MA, United States
Employees
60
Fiscal year end
1231
CIK
1681087
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PRMEPrime Medicine Inc. Common Stock | $567.7M | $4.6M | -4342.44% | -$1.35 | -6.72% | Buy |
| RGNXREGENXBIO Inc. Common Stock | $563.1M | $170.4M | -113.75% | -$3.76 | -0.58% | Buy |
| SCTXScribe Therapeutics Inc. Common Stock | $563M | $51.2M | -42.62% | — | +0.98% | Buy |
| ALLOAllogene Therapeutics Inc. Common Stock | $615M | $0.00 | — | -$0.87 | +1.14% | Buy |
| VALNValneva SE American Depositary Shares | $631.5M | — | — | -$1.36 | -0.45% | Buy |